The objective of the European Reference Networks is to ensure accessible diagnosis and treatment for rare diseases. This care should be consistent across the EU/EEA and rare disease type.
To ensure this quality of care, a review process was planned from the inception of the network with an ongoing Continuous Monitoring Programme (from 2018) and a 5-year evaluation process led by an external Independent Evaluation Body (IEB) (2023).
During 2023 the 5-year evaluation process using the Assessment, Monitoring, Evaluation, and Quality Improvement System (AMEQUIS) will take place for Endo-ERN HCPs established during the first call.
Endo-ERN will also have a review by the IEB that will include feedback from network HCPs. To support this process, Endo-ERN will also conduct an HCP Activity Review to document the support we receive from our members.
Continuous monitoring is ongoing for ALL members, and for those involved in the AMEQUIS 5-year evaluation process, it will help facilitate the Phase 2 Self-evaluation elements.
